Global Anti Obesity Drugs Market

Global Anti Obesity Drugs Market Size, Share, Growth Analysis, By Type(Prescription Drugs, OTC Drugs), By Distribution channel(Hospital Pharmacy, Retail Pharmacy) - Industry Forecast 2022-2028


Region: Global | Published Date: August, 2022 | Pages: 165

Global Anti Obesity Drugs Market Insights

Global anti obesity drugs market was valued at USD 2.8 billion in 2021, and it is expected to attain a value of USD 6.55 billion by 2028, at a CAGR of 12.92% over the prediction period (2022 – 2028).

The World Obesity Federation predicts that by the end of 2025, the global cost of obesity would have increased by over 50%, or by around US$ 1.2 trillion. Therefore, the main objective of pharmaceutical companies at the moment is to create mitigation methods to lessen the burden and shrink the fat population. Additionally, the industry is expected to present tremendous prospects for new companies because of the growing patient population and low treatment rates. Additionally, the introduction of initiatives to educate people about obesity and the development of reimbursement policies are projected to fuel product demand during the projection period.

Due to a spike in the sales of approved pharmaceuticals for the COVID-19 emergency, the COVID-19 pandemic has had a favorable effect on the world market for anti-obesity medications. Additionally, pharmaceutical firms are putting a lot of effort into keeping the pandemic's supply and demand in check in order to sustain their profits. Due to their increased risk of developing the disease, health organizations have released the essential guidelines and recommendations for the management of overweight and obese patients in the COVID-19 era. Furthermore, the widespread application of strict lockdown measures has led to a sedentary lifestyle and a work-from-home environment that have both contributed to weight increase. During the pandemic, this is projected to have a higher effect on the sales of drugs for treating obesity.

To get more reports on the above market click here to Buy The Report

Global Anti Obesity Drugs Market Segmental Analysis

The global anti obesity drugs market is segmented based on type, distribution channel, and region. Based on type, the market is segmented into prescription drugs and OTC drugs. On the basis of distribution channel, the market can be bifurcated into hospital pharmacy, retail pharmacy, online pharmacy. The regional insights of the market are into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa.

Analysis by Type

The majority of the market share was occupied by the category of prescription medications. The majority of the reason for the segment's domination is the accessibility of therapeutically effective weight management medications, whether they have a central or peripheral action. Another element influencing the demand for the product is the rising prevalence of obesity cases in the population as a result of high alcohol, fast food, and sedentary lifestyle adoption. For instance, the World Obesity Federation estimates that 650 million individuals worldwide are obese at the moment.

On the other hand, due to the branded drugs' patents expiring, over-the-counter medications are gradually gaining ground in the market. Due to a lack of public understanding about the importance of managing weight loss, the segment has a smaller market share.

Analysis by Distribution Channel

Due to a growth in patient visits and the sales of prescription medications for weight reduction, the hospital pharmacy segment currently has the greatest share in the world. Due to the availability of low-cost medications, people also have a strong preference for shopping often at neighboring pharmacies, which has contributed to the expansion of the retail pharmacy sector. Due to the development of online platforms for the delivery of prescription and over-the-counter medications to patients, it is estimated that the online pharmacy market would expand significantly.

To get detailed analysis on other segments, Request For Sample Report

Global Anti Obesity Drugs Market Regional Insights

The North American market has a value of US$ 964.8 million. This region’s dominance can be attributed to the US's strong players and the rising popularity of obesity control products. Due to its efforts in R&D for the creation of therapeutically effective medications, Europe currently occupies the second-place position in the market. Growth is anticipated during the projection period as a result of this as well as rising public awareness of the advantages of weight loss.

Due to the rising number of clinical studies on the management of obesity and the rising prevalence of obesity-related conditions like diabetes and cardiovascular diseases in the region, Asia Pacific is also expected to exhibit a high CAGR. Contrarily, Latin America and the Middle East & Africa are likely to experience relatively slower growth due to low levels of public awareness and a consequently lower demand for anti-obesity medications in those regions.

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Global Anti Obesity Drugs Market Dynamics

Driver

  • Growing worries about appropriate management of obesity have been sparked by the population's significant increase in sufferers. For instance, the World Obesity Federation estimates that 650 million people and 120 million children worldwide are obese at the moment. Additionally, it costs about US$ 2 trillion yearly to manage obesity. Additionally, according to the Centers for Disease Control and Prevention (CDC), 42.5% of US individuals aged 20 and older are obese. The demand for anti-obesity medications is expected to rise during the forecast period due to patients' increased knowledge of the importance of managing weight gain promptly in emerging economies.

Restraint 

  • The prevalence of obesity is rising internationally, yet treatment rates for the illness are still low due to inadequate education about weight control and erroneous public perceptions. Only 2% of the whole obese population is treated with prescription drugs, according to our study. This is mostly to blame for the reduced drug acceptance, which would hinder market expansion. Another factor limiting the market's growth is the presence of a small number of major players who concentrate on the development of treatments for obesity, as well as the negative effects of these medications.

Speak to one of our ABIRAW analyst for your custom requirements before the purchase of this report

Global Anti Obesity Drugs Market Competitive Landscape

The top players are concentrated on inorganic expansion tactics such as teaming up with successful individuals and national initiatives or programmes that advertise their goods. As a result, these brands are known earlier than other brands in the industry under investigation. Due to the disease's great prevalence, there is moderate to intense intergroup conflict.

Top Players in the Global Anti Obesity Drugs Market 

  • Alizyme (UK)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb (US)
  • Currax Pharmaceuticals LLC (US)
  • F. Hoffmann-La Roche AG (Switzerland)
  • GlaxoSmithKline PLC (UK)
  • Merck & Co. Inc. (US)
  • Norgine BV (Netherlands)
  • Novo Nordisk AS (Denmark)
  • Pfizer Inc. (US)
  • Rhythm Pharmaceuticals (US)
  • Takeda Pharmaceuticals (Japan)
  • Vivus Inc. (US)
  • Zafgan (US)
  • Zydus Cadila (US)

Recent Developments

  • In June 2021, Semaglutide 2.4 mg has been approved by the US Food and Drug Administration (FDA) for use in conjunction with a reduced-calorie diet and increased physical activity in adults who are obese or overweight and have at least one weight-related condition (such as high blood pressure, cholesterol, or T2D).
  • In January 2021, Novo Nordisk AS and the start-up Fauna Bio will research the chemicals and metabolic pathways that control metabolism in hibernating animals which will be part of a cooperation agreement, in an effort to find novel therapeutic treatments for obesity.

Global Anti Obesity Drugs Key Market Trends

  • The development of various possible therapeutic compounds that target both Type 2 diabetes mellitus and obesity has also become a major trend among companies competing in the anti-obesity industry. The rising prevalence of Type 2 diabetes and obesity is motivating manufacturers and researchers to develop medications that can treat both conditions. Therefore, it is anticipated that the rise in unhealthy eating patterns, sedentary lifestyles, and the obese population will propel market expansion throughout the forecast period.

Global Anti Obesity Drugs Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates and Analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.

According to our analysis, the global anti obesity drugs market is segmented based on type and distribution channel. The majority of the market share was occupied by the category of prescription medications. Due to a growth in patient visits and the sales of prescription medications for weight reduction, the hospital pharmacy segment currently has the greatest share in the world. The North American market has a value of USD 964.8 million. This region’s dominance can be attributed to the US's strong players and the rising popularity of obesity control products.

Report Metric Details
Market size value in 2021 USD 2.8 billion
Market size value in 2028 USD 6.55 billion
Growth Rate 12.92%
Base year 2021
Forecast period 2022 – 2028
Forecast Unit (Value) USD Billion
Segments covered
  • Type
    • Prescription Drugs, OTC Drugs
  • Distribution channel
    • Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Alizyme (UK)
  • Bayer AG (Germany)
  • Bristol-Myers Squibb (US)
  • Currax Pharmaceuticals LLC (US)
  • F. Hoffmann-La Roche AG (Switzerland)
  • GlaxoSmithKline PLC (UK)
  • Merck & Co. Inc. (US)
  • Norgine BV (Netherlands)
  • Novo Nordisk AS (Denmark)
  • Pfizer Inc. (US)
  • Rhythm Pharmaceuticals (US)
  • Takeda Pharmaceuticals (Japan)
  • Vivus Inc. (US)
  • Zafgan (US)
  • Zydus Cadila (US)
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Global Anti Obesity Drugs Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Global Anti Obesity Drugs Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Global Anti Obesity Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Anti Obesity Drugs Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Anti Obesity Drugs Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Global Anti Obesity Drugs Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$3,500
BUY NOW GET SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

SPEAK TO AN ANALYST

FAQ's

Global anti obesity drugs market was valued at USD 2.8 billion in 2021, and it is expected to attain a value of USD 6.55 billion by 2028, at a CAGR of 12.92% over the prediction period (2022 – 2028).

The top players are concentrated on inorganic expansion tactics such as teaming up with successful individuals and national initiatives or programmes that advertise their goods. As a result, these brands are known earlier than other brands in the industry under investigation. Due to the disease's great prevalence, there is moderate to intense intergroup conflict.'Alizyme (UK)','Bayer AG (Germany)','Bristol-Myers Squibb (US)','Currax Pharmaceuticals LLC (US)','F. Hoffmann-La Roche AG (Switzerland)','GlaxoSmithKline PLC (UK)','Merck & Co. Inc. (US)','Norgine BV (Netherlands)','Novo Nordisk AS (Denmark)','Pfizer Inc. (US)','Rhythm Pharmaceuticals (US)','Takeda Pharmaceuticals (Japan)','Vivus Inc. (US)','Zafgan (US)','Zydus Cadila (US)'

Growing worries about appropriate management of obesity have been sparked by the population's significant increase in sufferers. For instance, the World Obesity Federation estimates that 650 million people and 120 million children worldwide are obese at the moment. Additionally, it costs about US$ 2 trillion yearly to manage obesity. Additionally, according to the Centers for Disease Control and Prevention (CDC), 42.5% of US individuals aged 20 and older are obese. The demand for anti-obesity medications is expected to rise during the forecast period due to patients' increased knowledge of the importance of managing weight gain promptly in emerging economies.

The development of various possible therapeutic compounds that target both Type 2 diabetes mellitus and obesity has also become a major trend among companies competing in the anti-obesity industry. The rising prevalence of Type 2 diabetes and obesity is motivating manufacturers and researchers to develop medications that can treat both conditions. Therefore, it is anticipated that the rise in unhealthy eating patterns, sedentary lifestyles, and the obese population will propel market expansion throughout the forecast period.

The North American market has a value of US$ 964.8 million. This region’s dominance can be attributed to the US's strong players and the rising popularity of obesity control products. Due to its efforts in R&D for the creation of therapeutically effective medications, Europe currently occupies the second-place position in the market. Growth is anticipated during the projection period as a result of this as well as rising public awareness of the advantages of weight loss.

Speak With Our Analyst

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Anti Obesity Drugs Market

Product ID:

$3,500
BUY NOW GET SAMPLE